Alzheimer’s disease (AD) is an incurable, chronic, progressive neurodegenerative disorder characterized by memory loss and cognitive impairment. There are treatments, but at this time, nothing can halt the inexorable progression to eventual death. Although the pathogenesis of AD is complex and multi-factorial, prevention of amyloid and tau accumulation has been the primary approach to development of new therapies. However, AD begins with changes in bioenergetics and disruption of mitochondrial function affecting axonal transport and synaptic plasticity prior to frank neuronal degeneration Mitochondrial defects in AD lead to insufficient ATP synthesis and oxidative stress as well as excessive mitochondrial fission, reduced fusion and faulty mitophagy. P110 is a seven-amino acid peptide that restores mitochondrial dynamics by acting as an inhibitor of mitochondrial fission.